Rockwell Medical, Inc.

NasdaqCM:RMTI Voorraadrapport

Marktkapitalisatie: US$112.9m

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Rockwell Medical Beheer

Beheer criteriumcontroles 2/4

De CEO Rockwell Medical's is Mark Strobeck, benoemd in Jul2022, heeft een ambtstermijn van 2.25 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 1.05M, bestaande uit 53.7% salaris en 46.3% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.07% van de aandelen van het bedrijf, ter waarde $ 85.88K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.1 jaar en 4.3 jaar.

Belangrijke informatie

Mark Strobeck

Algemeen directeur

US$1.1m

Totale compensatie

Percentage CEO-salaris53.7%
Dienstverband CEO2.3yrs
Eigendom CEO0.07%
Management gemiddelde ambtstermijn2.1yrs
Gemiddelde ambtstermijn bestuur4.3yrs

Recente managementupdates

Recent updates

The Market Lifts Rockwell Medical, Inc. (NASDAQ:RMTI) Shares 28% But It Can Do More

Sep 29
The Market Lifts Rockwell Medical, Inc. (NASDAQ:RMTI) Shares 28% But It Can Do More

Rockwell Medical: The Turnaround Is Looking Real

Sep 15

Rockwell Medical, Inc. Just Reported A Surprise Profit And Analysts Updated Their Estimates

Aug 11
Rockwell Medical, Inc. Just Reported A Surprise Profit And Analysts Updated Their Estimates

Rockwell Medical, Inc.'s (NASDAQ:RMTI) Subdued P/S Might Signal An Opportunity

Jul 12
Rockwell Medical, Inc.'s (NASDAQ:RMTI) Subdued P/S Might Signal An Opportunity

Does Rockwell Medical (NASDAQ:RMTI) Have A Healthy Balance Sheet?

May 08
Does Rockwell Medical (NASDAQ:RMTI) Have A Healthy Balance Sheet?

Is Rockwell Medical (NASDAQ:RMTI) A Risky Investment?

Feb 06
Is Rockwell Medical (NASDAQ:RMTI) A Risky Investment?

Rockwell Medical, Inc. (NASDAQ:RMTI) Doing What It Can To Lift Shares

Dec 25
Rockwell Medical, Inc. (NASDAQ:RMTI) Doing What It Can To Lift Shares

Is Rockwell Medical (NASDAQ:RMTI) Using Too Much Debt?

Oct 11
Is Rockwell Medical (NASDAQ:RMTI) Using Too Much Debt?

Is Rockwell Medical (NASDAQ:RMTI) Weighed On By Its Debt Load?

Jun 02
Is Rockwell Medical (NASDAQ:RMTI) Weighed On By Its Debt Load?

Is There Now An Opportunity In Rockwell Medical, Inc. (NASDAQ:RMTI)?

Oct 25
Is There Now An Opportunity In Rockwell Medical, Inc. (NASDAQ:RMTI)?

An Intrinsic Calculation For Rockwell Medical, Inc. (NASDAQ:RMTI) Suggests It's 46% Undervalued

Sep 02
An Intrinsic Calculation For Rockwell Medical, Inc. (NASDAQ:RMTI) Suggests It's 46% Undervalued

Rockwell Medical Q2 Earnings Preview

Aug 12

Rockwell Medical: Triferic Remains Key Despite Sluggish Growth Profile

Mar 02

Rockwell Medical: Down But By No Means Out

Oct 05

Rockwell Medical pops 6% on licensing deal for Triferic AVNU in Turkey

Jun 08

Health Check: How Prudently Does Rockwell Medical (NASDAQ:RMTI) Use Debt?

Mar 08
Health Check: How Prudently Does Rockwell Medical (NASDAQ:RMTI) Use Debt?

Some Rockwell Medical, Inc. (NASDAQ:RMTI) Analysts Just Made A Major Cut To Next Year's Estimates

Feb 10
Some Rockwell Medical, Inc. (NASDAQ:RMTI) Analysts Just Made A Major Cut To Next Year's Estimates

How Many Rockwell Medical, Inc. (NASDAQ:RMTI) Shares Do Institutions Own?

Jan 18
How Many Rockwell Medical, Inc. (NASDAQ:RMTI) Shares Do Institutions Own?

Analyse CEO-vergoeding

Hoe is Mark Strobeck's beloning veranderd ten opzichte van Rockwell Medical's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Jun 30 2024n/an/a

-US$5m

Mar 31 2024n/an/a

-US$9m

Dec 31 2023US$1mUS$566k

-US$9m

Sep 30 2023n/an/a

-US$9m

Jun 30 2023n/an/a

-US$12m

Mar 31 2023n/an/a

-US$13m

Dec 31 2022US$978kUS$267k

-US$19m

Compensatie versus markt: De totale vergoeding ($USD 1.05M ) Mark } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 677.23K ).

Compensatie versus inkomsten: De vergoeding van Mark is gestegen terwijl het bedrijf verliesgevend is.

CEO

Mark Strobeck (53 yo)

2.3yrs

Tenure

US$1,054,169

Compensatie

Dr. Mark Strobeck, Ph D., serves as Independent Director at Windtree Therapeutics, Inc. since June 2023 and is its Lead Independent Director since August 13, 2024. He has served as the President, Chief Exe...

Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Mark Strobeck
President2.3yrsUS$1.05m0.070%
$ 78.7k
Jesse Neri
Senior Vice President of Financeless than a yearUS$453.18kgeen gegevens
Megan Timmins
Executive VP3.2yrsUS$660.29k0.036%
$ 40.5k
Timothy Chole
Senior VP & Chief Commercial Officerless than a yeargeen gegevens0.041%
$ 46.7k
Heather Hunter
Senior VP & Chief Corporate Affairs Officer2.1yrsgeen gegevensgeen gegevens

2.1yrs

Gemiddelde duur

51yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van RMTI wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.1 jaar).

Bestuursleden

NaamPositieTenureCompensatieEigendom
Mark Strobeck
President2.3yrsUS$1.05m0.070%
$ 78.7k
John Cooper
Independent Director7.1yrsUS$142.27k0.11%
$ 126.0k
Robert Radie
Independent Chairman4.6yrsUS$170.00k0.11%
$ 119.0k
Allen Nissenson
Independent Director4.3yrsUS$127.94k0.10%
$ 115.6k
Joan Lau
Independent Directorless than a yearUS$89.51k0.0065%
$ 7.3k
Mark Ravich
Independent Director7.3yrsUS$128.29k0.23%
$ 255.8k
Andrea Smiley
Independent Director3.8yrsUS$130.56k0.10%
$ 113.7k

4.3yrs

Gemiddelde duur

61yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van RMTI wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.3 jaar).